These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 37723839)
1. Engineering extracellular vesicles to deliver CRISPR ribonucleoprotein for gene editing. Whitley JA; Cai H J Extracell Vesicles; 2023 Sep; 12(9):e12343. PubMed ID: 37723839 [TBL] [Abstract][Full Text] [Related]
2. Engineered extracellular vesicles as versatile ribonucleoprotein delivery vehicles for efficient and safe CRISPR genome editing. Yao X; Lyu P; Yoo K; Yadav MK; Singh R; Atala A; Lu B J Extracell Vesicles; 2021 Mar; 10(5):e12076. PubMed ID: 33747370 [TBL] [Abstract][Full Text] [Related]
3. Small extracellular vesicle-mediated CRISPR-Cas9 RNP delivery for cardiac-specific genome editing. Mun D; Kang JY; Kim H; Yun N; Joung B J Control Release; 2024 Jun; 370():798-810. PubMed ID: 38754633 [TBL] [Abstract][Full Text] [Related]
4. Encapsulating Cas9 into extracellular vesicles by protein myristoylation. Whitley JA; Kim S; Lou L; Ye C; Alsaidan OA; Sulejmani E; Cai J; Desrochers EG; Beharry Z; Rickman CB; Klingeborn M; Liu Y; Xie ZR; Cai H J Extracell Vesicles; 2022 Apr; 11(4):e12196. PubMed ID: 35384352 [TBL] [Abstract][Full Text] [Related]
5. Cell-derived extracellular vesicles for CRISPR/Cas9 delivery: engineering strategies for cargo packaging and loading. Liang Y; Iqbal Z; Wang J; Xu L; Xu X; Ouyang K; Zhang H; Lu J; Duan L; Xia J Biomater Sci; 2022 Jul; 10(15):4095-4106. PubMed ID: 35766814 [TBL] [Abstract][Full Text] [Related]
6. Comparative analysis of lipid Nanoparticle-Mediated delivery of CRISPR-Cas9 RNP versus mRNA/sgRNA for gene editing in vitro and in vivo. Walther J; Porenta D; Wilbie D; Seinen C; Benne N; Yang Q; de Jong OG; Lei Z; Mastrobattista E Eur J Pharm Biopharm; 2024 Mar; 196():114207. PubMed ID: 38325664 [TBL] [Abstract][Full Text] [Related]
7. Small extracellular vesicles (sEVs)-based gene delivery platform for cell-specific CRISPR/Cas9 genome editing. Dubey S; Chen Z; Jiang YJ; Talis A; Molotkov A; Ali A; Mintz A; Momen-Heravi F Theranostics; 2024; 14(7):2777-2793. PubMed ID: 38773978 [TBL] [Abstract][Full Text] [Related]
8. Strategies in the delivery of Cas9 ribonucleoprotein for CRISPR/Cas9 genome editing. Zhang S; Shen J; Li D; Cheng Y Theranostics; 2021; 11(2):614-648. PubMed ID: 33391496 [TBL] [Abstract][Full Text] [Related]
9. Extracellular vesicle-mediated delivery of CRISPR/Cas9 ribonucleoprotein complex targeting proprotein convertase subtilisin-kexin type 9 (Pcsk9) in primary mouse hepatocytes. Ilahibaks NF; Kluiver TA; de Jong OG; de Jager SCA; Schiffelers RM; Vader P; Peng WC; Lei Z; Sluijter JPG J Extracell Vesicles; 2024 Jan; 13(1):e12389. PubMed ID: 38191764 [TBL] [Abstract][Full Text] [Related]
10. Packaging and Uncoating of CRISPR/Cas Ribonucleoproteins for Efficient Gene Editing with Viral and Non-Viral Extracellular Nanoparticles. Mazurov D; Ramadan L; Kruglova N Viruses; 2023 Mar; 15(3):. PubMed ID: 36992399 [TBL] [Abstract][Full Text] [Related]
11. Preparation of NanoMEDIC Extracellular Vesicles to Deliver CRISPR-Cas9 Ribonucleoproteins for Genomic Exon Skipping. Watanabe K; Gee P; Hotta A Methods Mol Biol; 2023; 2587():427-453. PubMed ID: 36401042 [TBL] [Abstract][Full Text] [Related]
12. Functionalized extracellular nanovesicles as advanced CRISPR delivery systems. Wang S; Kong H; Zhuo C; Liu L; Lv S; Cheng D; Lao YH; Tao Y; Li M Biomater Sci; 2024 Jul; 12(14):3480-3499. PubMed ID: 38808607 [TBL] [Abstract][Full Text] [Related]
13. Development of CRISPR/Cas Delivery Systems for In Vivo Precision Genome Editing. Chen Y; Ping Y Acc Chem Res; 2023 Aug; 56(16):2185-2196. PubMed ID: 37525893 [TBL] [Abstract][Full Text] [Related]
14. Extracellular vesicles as a potential delivery platform for CRISPR-Cas based therapy in epithelial ovarian cancer. Godbole N; Quinn A; Carrion F; Pelosi E; Salomon C Semin Cancer Biol; 2023 Nov; 96():64-81. PubMed ID: 37820858 [TBL] [Abstract][Full Text] [Related]
15. Iron-Confined CRISPR/Cas9-Ribonucleoprotein Delivery System for Redox-Responsive Gene Editing. Qiu L; Sun M; Chen L; Jiang J; Fu Z; Wang Y; Bi Y; Guo Q; Bai H; Chen S; Gao L; Chang G Small; 2024 Jul; 20(30):e2309431. PubMed ID: 38402425 [TBL] [Abstract][Full Text] [Related]
16. Poly-sgRNA/siRNA ribonucleoprotein nanoparticles for targeted gene disruption. Ha JS; Lee JS; Jeong J; Kim H; Byun J; Kim SA; Lee HJ; Chung HS; Lee JB; Ahn DR J Control Release; 2017 Mar; 250():27-35. PubMed ID: 28167287 [TBL] [Abstract][Full Text] [Related]
17. Current and prospective strategies for advancing the targeted delivery of CRISPR/Cas system via extracellular vesicles. Huang X; Li A; Xu P; Yu Y; Li S; Hu L; Feng S J Nanobiotechnology; 2023 Jun; 21(1):184. PubMed ID: 37291577 [TBL] [Abstract][Full Text] [Related]
18. Viral vectors and extracellular vesicles: innate delivery systems utilized in CRISPR/Cas-mediated cancer therapy. Ahmadi SE; Soleymani M; Shahriyary F; Amirzargar MR; Ofoghi M; Fattahi MD; Safa M Cancer Gene Ther; 2023 Jul; 30(7):936-954. PubMed ID: 36854897 [TBL] [Abstract][Full Text] [Related]
19. Engineered Extracellular Vesicle-Delivered CRISPR/CasRx as a Novel RNA Editing Tool. Li T; Zhang L; Lu T; Zhu T; Feng C; Gao N; Liu F; Yu J; Chen K; Zhong J; Tang Q; Zhang Q; Deng X; Ren J; Zeng J; Zhou H; Zhu J Adv Sci (Weinh); 2023 Apr; 10(10):e2206517. PubMed ID: 36727818 [TBL] [Abstract][Full Text] [Related]
20. Different Methods of Delivering CRISPR/Cas9 Into Cells. Chandrasekaran AP; Song M; Kim KS; Ramakrishna S Prog Mol Biol Transl Sci; 2018; 159():157-176. PubMed ID: 30340786 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]